Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.74
NAS:CDXC's Cash-to-Debt is ranked lower than
63% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NAS:CDXC: 2.74 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CDXC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1  Med: 4.07 Max: No Debt
Current: 2.74
Equity-to-Asset 0.51
NAS:CDXC's Equity-to-Asset is ranked lower than
52% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:CDXC: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CDXC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.43 Max: 0.76
Current: 0.51
0.28
0.76
Piotroski F-Score: 4
Altman Z-Score: 4.19
Beneish M-Score: -0.81
WACC vs ROIC
11.66%
-26.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -8.38
NAS:CDXC's Operating Margin % is ranked higher than
69% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. NAS:CDXC: -8.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CDXC' s Operating Margin % Range Over the Past 10 Years
Min: -100.22  Med: -34.16 Max: -8.37
Current: -8.38
-100.22
-8.37
Net Margin % -10.92
NAS:CDXC's Net Margin % is ranked higher than
67% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. NAS:CDXC: -10.92 )
Ranked among companies with meaningful Net Margin % only.
NAS:CDXC' s Net Margin % Range Over the Past 10 Years
Min: -100.45  Med: -35.19 Max: -10.92
Current: -10.92
-100.45
-10.92
ROE % -31.84
NAS:CDXC's ROE % is ranked higher than
58% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. NAS:CDXC: -31.84 )
Ranked among companies with meaningful ROE % only.
NAS:CDXC' s ROE % Range Over the Past 10 Years
Min: -3800  Med: -101.53 Max: -31.84
Current: -31.84
-3800
-31.84
ROA % -15.99
NAS:CDXC's ROA % is ranked higher than
67% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. NAS:CDXC: -15.99 )
Ranked among companies with meaningful ROA % only.
NAS:CDXC' s ROA % Range Over the Past 10 Years
Min: -3800  Med: -50.81 Max: -15.21
Current: -15.99
-3800
-15.21
ROC (Joel Greenblatt) % -31.42
NAS:CDXC's ROC (Joel Greenblatt) % is ranked higher than
72% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. NAS:CDXC: -31.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CDXC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -381.66  Med: -157.99 Max: -31.42
Current: -31.42
-381.66
-31.42
3-Year Revenue Growth Rate 33.10
NAS:CDXC's 3-Year Revenue Growth Rate is ranked higher than
71% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:CDXC: 33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CDXC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.3 Max: 33.1
Current: 33.1
0
33.1
3-Year EBITDA Growth Rate -22.60
NAS:CDXC's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:CDXC: -22.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CDXC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.5  Med: 6.8 Max: 143.4
Current: -22.6
-47.5
143.4
3-Year EPS without NRI Growth Rate -12.60
NAS:CDXC's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:CDXC: -12.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CDXC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41  Med: 0 Max: 146.6
Current: -12.6
-41
146.6
GuruFocus has detected 4 Warning Signs with ChromaDex Corp $NAS:CDXC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CDXC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:CDXC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2833
Compare:NAS:AGLE, NAS:CRME, NAS:NOVN, NAS:BDSI, NAS:CTRV, NAS:PRQR, OTCPK:ORGS, NAS:ECYT, AMEX:NAVB, AMEX:XXII, NAS:VCEL, OTCPK:IMMVF, NAS:CORI, OTCPK:CYDY, NAS:AFMD, AMEX:RNN, NAS:SBPH, OTCPK:HPPI, NAS:EIGR, OTCPK:MCUJF » details
Traded in other countries:OCD1.Germany,
ChromaDex Corp through its subsidiaries, supplies phytochemical referance standards to research an array of potential attributes & reference materials, related contract services, technical consulting & proprietary ingredients.

ChromaDex Corp was formed as a California corporation on February 19, 2000. The Company, along with its subsidiaries supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of potential attributes, and reference materials, related contract services, technical consulting and proprietary ingredients. Through its subsidiaries, the Company provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks. The products and services includes dietary supplement and food ingredients, supply of reference standards, materials & kits, supply of fine chemicals and phytochemicals, contract services, consulting services and process development. The Company uses international distributors to market and sell to several foreign countries or markets. Its sales model for products and services is based on direct, inside technical sales. Its operations are subject to regulation by various United States federal agencies and similar state and international agencies, including the FDA, the Federal Trade Commission, the Department of Commerce, the Department of Transportation, the Department of Agriculture and other state and international agencies.

Ratios

vs
industry
vs
history
Forward PE Ratio 16.18
CDXC's Forward PE Ratio is ranked higher than
68% of the 78 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CDXC: 16.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 9.73
CDXC's PB Ratio is ranked lower than
82% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CDXC: 9.73 )
Ranked among companies with meaningful PB Ratio only.
CDXC' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 17.77 Max: 69.44
Current: 9.73
2.46
69.44
PS Ratio 3.62
CDXC's PS Ratio is ranked higher than
76% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CDXC: 3.62 )
Ranked among companies with meaningful PS Ratio only.
CDXC' s PS Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.54 Max: 103.45
Current: 3.62
1.13
103.45
EV-to-EBIT -37.99
CDXC's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. CDXC: -37.99 )
Ranked among companies with meaningful EV-to-EBIT only.
CDXC' s EV-to-EBIT Range Over the Past 10 Years
Min: -383.7  Med: -25 Max: -2.2
Current: -37.99
-383.7
-2.2
EV-to-EBITDA -45.46
CDXC's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. CDXC: -45.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDXC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1187.8  Med: -27.5 Max: -2.6
Current: -45.46
-1187.8
-2.6
Current Ratio 1.77
CDXC's Current Ratio is ranked lower than
68% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CDXC: 1.77 )
Ranked among companies with meaningful Current Ratio only.
CDXC' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.73 Max: 4.3
Current: 1.77
0.92
4.3
Quick Ratio 0.88
CDXC's Quick Ratio is ranked lower than
78% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CDXC: 0.88 )
Ranked among companies with meaningful Quick Ratio only.
CDXC' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 0.87 Max: 3.05
Current: 0.88
0.5
3.05
Days Inventory 164.80
CDXC's Days Inventory is ranked lower than
56% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. CDXC: 164.80 )
Ranked among companies with meaningful Days Inventory only.
CDXC' s Days Inventory Range Over the Past 10 Years
Min: 39.68  Med: 140.05 Max: 197.17
Current: 164.8
39.68
197.17
Days Sales Outstanding 79.67
CDXC's Days Sales Outstanding is ranked lower than
68% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CDXC: 79.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.27  Med: 40.64 Max: 79.67
Current: 79.67
28.27
79.67
Days Payable 146.54
CDXC's Days Payable is ranked higher than
65% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. CDXC: 146.54 )
Ranked among companies with meaningful Days Payable only.
CDXC' s Days Payable Range Over the Past 10 Years
Min: 40.67  Med: 126.15 Max: 167.87
Current: 146.54
40.67
167.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
CDXC's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CDXC: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CDXC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -55.3  Med: -20.2 Max: -2.5
Current: -2.5
-55.3
-2.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 16.19
CDXC's Price-to-Net-Current-Asset-Value is ranked lower than
76% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CDXC: 16.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CDXC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 15.81  Med: 33 Max: 65.14
Current: 16.19
15.81
65.14
Price-to-Tangible-Book 10.36
CDXC's Price-to-Tangible-Book is ranked lower than
77% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CDXC: 10.36 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CDXC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 10.12  Med: 17.59 Max: 29.04
Current: 10.36
10.12
29.04
Price-to-Median-PS-Value 0.55
CDXC's Price-to-Median-PS-Value is ranked higher than
78% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CDXC: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDXC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 0.91 Max: 2.27
Current: 0.55
0.34
2.27
Earnings Yield (Greenblatt) % -2.63
CDXC's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. CDXC: -2.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDXC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.69  Med: 0 Max: 441.48
Current: -2.63
-2.69
441.48

More Statistics

Revenue (TTM) (Mil) $26.81
EPS (TTM) $ -0.08
Beta1.22
Short Percentage of Float4.88%
52-Week Range $2.25 - 6.18
Shares Outstanding (Mil)37.54

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 45 85 87
EPS ($) 0.16 0.36 0.35
EPS without NRI ($) 0.16 0.36 0.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CDXC

Headlines

Articles On GuruFocus.com

More From Other Websites
CHROMADEX CORP. Financials Mar 23 2017
Chromadex Corp. :CDXC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Mar 22 2017
Edited Transcript of CDXC earnings conference call or presentation 17-Mar-17 5:00pm GMT Mar 20 2017
CHROMADEX CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 16 2017
CHROMADEX CORP. Files SEC form 10-K, Annual Report Mar 16 2017
Q4 2016 Chromadex Corp Earnings Release - After Market Close Mar 16 2017
ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017 Mar 10 2017
CHROMADEX CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 23 2017
A Letter from the ChromaDex Chief Executive Officer Feb 23 2017
Study Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving... Feb 22 2017
ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017 Feb 21 2017
CHROMADEX CORP. Files SEC form 8-K, Other Events Feb 17 2017
CHROMADEX CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 14 2017
ChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29% Feb 14 2017
ETFs with exposure to Chromadex Corp. : January 24, 2017 Jan 24 2017
ETFs with exposure to Chromadex Corp. : January 9, 2017 Jan 09 2017
CHROMADEX CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2017
ChromaDex Opens New State-of-the-Art Research and Development Center in Longmont Jan 05 2017
ChromaDex Opens New State-of-the-Art Research and Development Center in Longmont Jan 05 2017
ChromaDex to Present at the ICR Conference 2017 on January 11, 2017 Jan 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)